CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories
VANCOUVER, Washington, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential ...
Business Insider14d
Rural Communities at Risk: Global Liver Institute Champions Awareness for Rare Liver Diseases
Washington, D.C., Feb. 01, 2025 (GLOBE NEWSWIRE) -- As rural healthcare access shrinks across the United States and remains limited worldwide, Global Liver Institute (GLI) is shining a spotlight ...
Medscape15d
Hepatic Fibrosis -- Role of Hepatic Stellate Cell Activation
The paradigm of stellate ... by stellate cells, antagonists have been tested as both antifibrotic and portal hypotensive agents. Alternatively, delivery of NO to injured liver may have the same ...
Scientific American25d
Mysterious Blobs Found inside Cells Are Rewriting the Story of How Life Works
In 2009 a team of biophysicists led by Anthony A. Hyman of the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany, were studying specklelike structures called P ...
Frontiers26d
Liver sinusoidal endothelial cells regulate the balance between hepatic immunosuppression and immunosurveillance
Hepatocellular carcinoma (HCC) is initiated by chronic viral infections, chronic alcohol consumption, and/or a fatty diet that leads to liver injury, fibrosis, and cirrhosis. HCC patients have high ...
The EMBO Journal29d
SLC13A2 promotes hepatocyte metabolic remodeling and liver regeneration by enhancing de novo cholesterol biosynthesis
Metabolic requirements of dividing hepatocytes are prerequisite for liver regeneration after injury. In contrast to transcriptional dynamics during liver repair, its metabolic dependencies remain ...